Month: May 2022

Total Revenue Increases 11% Period-over-Period and PBRT Revenue Increases 33% SAN FRANCISCO, CA, May 12, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — American Shared Hospital Services (NYSE American: AMS) (the “Company”), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced financial results for the first quarter ending March 31, 2022. First Quarter 2022 Financial HighlightsTotal revenue in the first quarter was $4,847,000, an increase of 11.1% from the comparable period in 2021. Total proton therapy revenue and fractions increased 33.2% and 32.3%, respectively, period-over-period. Gamma Knife revenue and volumes for same centers in operation increased 7.2% and 1.9%, respectively, when compared to Gamma Knife volumes...

Key financial highlightsRevenue growth of 32.6%, reaching $51.9 M for Q3-FY2022 from $39.2 M for Q3-FY2021, driven by organic revenue growth of $6.0 M, or 15.3%, and acquisition growth of $6.7 M, or 17.3%; Adjusted EBITDA1 reached $5.3 M, or 10.3% of revenues, for Q3-FY2022, compared to $4.5 M, or 11.5% of revenues, for Q3-FY2021; and Adjusted net earnings1 amounted to $3.4 M or $0.038 per share for Q3-FY2022 compared to adjusted net earnings of $2.2 M or $0.027 per share for Q3-FY2021.Subsequent event highlightOn April 4, 2022, the Corporation announced that it had recently renewed its contract with its largest operation and maintenance customer, the City of Gulfport, Mississippi. The expanded four-year contract, valued at $55.5 M, brought the Corporation’s O&M backlog to $131.0 M on April 4, 2022. On April 12, 2022, the Corporation...

Cash position bolstered through debt financing to support operations into the fourth quarter of 2023 NEEDHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update. “2022 is off to a great start as we continue to advance our late-stage pipeline of novel oncolytic viral immunotherapies for cancer,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel. “Today, we are well positioned for major catalysts over the next 12 months, namely multiple clinical data readouts across our product candidates and advancement of our...

Phase 1 clinical trial of INB-100 in leukemia patients and INB-200 in newly diagnosed glioblastoma multiforme (GBM) patients continue to generate encouraging data. INB-100 patient update at European Group for Blood and Marrow Transplantation (EBMT) 48th Annual Meeting demonstrated that all three treated patients remain in morphologic complete response (CR) with two patients approaching relapse free survival of 21 to 23 months as of March 2022. INB-200 continues to enroll and treat patients in cohort 2 with one patient having received all three anticipated repeat doses of INB-200, the first-ever repeat dosing of a genetically modified gamma-delta T cell therapy. A clinical update is expected at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2022 (Abstract # 2044). In May 2022, IN8bio unveiled a new program focused...

Registrational study design for lead clinical asset, EB613, as the first oral PTH anabolic to treat post-menopausal women at high risk of osteoporosis, is underway Company reschedules conference call and webcast to Wednesday, May 18 at 8:00 AM EDT BOSTON and JERUSALEM, May 12, 2022 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced its financial and operating results for the quarter ended March 31, 2022. First Quarter 2022 and Recent Highlights EB613 Clinical Update: Entera’s lead clinical candidate, EB613, an oral formulation of human parathyroid hormone (1-34), or PTH, for the treatment of osteoporosis, is progressing towards a pivotal Phase 3 clinical trial. The FDA has completed the Chemistry Manufacturing and Control (CMC) review...

– Phase 3 Lumeos Clinical Trial of Botaretigene Sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) Actively Dosing Patients– Phase 1 AQUAx Study of AAV-hAQP1 for Radiation-Induced Xerostomia Completed Dosing of Both Unilateral and Bilateral Cohorts in the First Quarter of 2022 LONDON and NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) — MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the first quarter ended March 31, 2022 and provided an update on recent progress. “During the first quarter of this year, we continued to progress our lead program for the treatment of XLRP, botaretigene sparoparvovec, through pivotal development along with our partner Janssen,” said Alexandria Forbes, Ph.D., president and chief...

Total net revenues up 7.4% to $14.8 million in Q3 FY 2022 Annual recurring revenue (SaaS and Support) increased to a $26.2 million run rate CALABASAS, Calif., May 12, 2022 (GLOBE NEWSWIRE) — NETSOL Technologies, Inc. (Nasdaq: NTWK), a global business services and enterprise application solutions provider, reported results for the fiscal third quarter ended March 31, 2022. Fiscal Third Quarter 2022 and Recent Operational HighlightsSubscription (SaaS and Cloud) and support quarterly revenues increased 16% to $6.6 million. NETSOL’s U.S. based mobility startup Otoz expanded its digital automotive retail platform MINI Anywhere® for BMW® Group Financial Services in the U.S. for its key brand MINI®. MINI Anywhere is now live with 17 MINI dealerships, including 70%+ of the California MINI dealerships and 75% of all Pennsylvania dealerships....

Validive® Phase 2b/3 VOICE Trial Continues Enrolling Patients Toward InterimCamsirubicin Phase 1b Dose-Escalation Trial Clears 3rdDose Level, Now Enrolling 4th WILMETTE, Ill., May 12, 2022 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced first quarter 2022 financial results and summarized recent program developments. Recent Program Developments Validive – International Phase 2b/3 VOICE Clinical Trial, Actively RecruitingThe VOICE trial continues to enroll patients and add additional clinical sites, with the interim analysis anticipated to occur in 2H-2022.Camsirubicin – Phase 1b Dose-Escalation Trial, Actively...

First Quarter Highlights – 2022 vs. 2021Revenue up 39% to $6.2 million from $4.4 millionOperating income increases 6-fold to $0.6 million from $0.1 millionNet income of $0.5 million vs. $1.2 million in year-ago first quarter when Company booked $1.0 million in PPP loan forgiveness in other incomeAdjusted EBITDA of $0.9 million, up 156% from $0.4 millionCompany buys back 33,550 shares of stock in the first quarterCASTLE ROCK, Colo., May 12, 2022 (GLOBE NEWSWIRE) — Where Food Comes From, Inc. (WFCF) (Nasdaq: WFCF), the most trusted resource for independent, third-party verification of food production practices in North America, today announced financial results for its first quarter ended March 31, 2022. “First quarter revenue growth reflected continued momentum in our verification and certification segment, including...